



MEDIGARD LIMITED

Office 14A, Tedder Terraces, 26-30 Tedder Avenue, Main Beach QLD 4217

Telephone +61 7 5528 0370; Fax +61 7 5528 0275

E-mail office@medigard.com.au www.medigard.com.au

ABN 49 090 003 044

21 September, 2010

Manager of Company Announcements
Australian Stock Exchange Limited
Level 6, 20 Bridge Street
SYDNEY NSW 2000

By e-lodgement

No of pages: 1 inclusive

Grant of Patent for 3mL Syringe in South Africa

Medigard Limited (ASX:MGZ) is delighted to announce that its patent application in the Republic of South Africa for its 3mL Safety Vacuum Retractable Syringe has now been granted. This provides Medigard with exclusive patent protection in South Africa until 9 March, 2027.

“Whilst South Africa may not be a priority market for us at present, the fact that our patent has been granted in one of the jurisdictions in which we have applied bodes well for successful applications in other jurisdictions” said CEO, Peter Emery. “It establishes a legally enforceable foothold on the African continent, a land in great need of safety syringes” he added.

Peter Emery
Chief Executive Officer

For further information contact:
Peter Emery, Telephone (07) 5528 0370